[Market Focus] HanAll Biopharma Plunges Over 14% on Phase 3 Clinical Trial Failure
HanAll Biopharma is plunging by over 14% in early trading on April 3.
As of 9:13 a.m. on this day, HanAll Biopharma was trading at 36,550 won on the Korea Exchange, down 14.43% from the previous session.
This sharp drop is believed to be driven by reports that HanAll Biopharma's candidate treatment for thyroid eye disease (TED) failed to achieve statistical efficacy in Phase 3 clinical trials.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
On April 2, HanAll Biopharma disclosed the main results of its Phase 3 clinical trial for the thyroid eye disease candidate drug "Batoclimab." The study targeted adult patients with active thyroid eye disease, administering a high dose (680mg) and a low dose (340mg) of Batoclimab for 12 weeks each, and measured the "proptosis response rate" at week 24 as the primary endpoint. However, statistical efficacy was not demonstrated.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.